): Deregulated expression of the c-Myc oncoprotein occurs in many human malignancies, yet the mechanisms by which c-Myc promotes tumorigenesis remain ambiguous. There is some evidence that c-Myc could effect cell transformation by functioning as a transcriptional activator of genes presumably involved in cell proliferation. Its ability to transactivate reporter genes through upstream specific DNA binding sites (CACGTG, also referred to as E-boxes) has been well-documented by several investigators. The study of c-Myc oncoprotein function has been clouded by reports of c-Myc mediated transcriptional repression, an activity of unknown biological significance. Preliminary evidence from the investigators' laboratory demonstrates that c-Myc can repress the adenoviral major late promoter through the initiation (Inr), a pyrimidine-rich promoter element that is present in many TATA-less genes. They have also observed that a portion of the amino-terminal c-Myc transactivation domain is required for the repressive activity through the Inr. A lymphoma-derived Myc mutant that bears a substitution (115-Phe) within the domain necessary for transcriptional repression is a stronger repressor of the adML promoter and confers a greater potential for anchorage-independent cell growth than wild-type c-Myc, suggesting that transcriptional repression may play a role in c-Myc mediated cell transformation in vivo. This proposal will further delineate the link between c-Myc mediated transcriptional repression through Inr and cell transformation. Several lymphoma-derived Myc proteins that contain mutations within the region required for transcriptional repression through the Inr will be examined with regard to their transcriptional activity and transformation ability. Investigation of c-Myc interaction in vivo with two putative target genes, ornithine decarboxylase (ODC) and albumin will be pursued because ODC, a growth-regulated gene, has been reported to be transactivated by c-Myc through its E-boxes whereas albumin, a gene expressed in differentiated cells, has been reported to be repressed by c-Myc through its Inr. To further establish c-Myc function in vivo, the technique of representational difference analysis will be applied to identify novel target genes that are either transactivated or repressed by c-Myc in regenerating liver, an in vivo model of cell proliferation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Physician Scientist Award (K11)
Project #
5K11CA064258-05
Application #
6172182
Study Section
Cancer Research Manpower and Education Review Committee (CRME)
Program Officer
Vargosko, Andrew J
Project Start
1996-07-01
Project End
2002-06-30
Budget Start
2000-07-01
Budget End
2002-06-30
Support Year
5
Fiscal Year
2000
Total Cost
$90,665
Indirect Cost
Name
Johns Hopkins University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Cruz-Correa, M; Poonawala, A; Abraham, S C et al. (2002) Endoscopic findings predict the histologic diagnosis in gastrointestinal graft-versus-host disease. Endoscopy 34:808-13
Prescott, J E; Osthus, R C; Lee, L A et al. (2001) A novel c-Myc-responsive gene, JPO1, participates in neoplastic transformation. J Biol Chem 276:48276-84
Kim, S; Zeller, K; Dang, C V et al. (2001) A strategy to identify differentially expressed genes using representational difference analysis and cDNA arrays. Anal Biochem 288:141-148
Kim, S; Li, Q; Dang, C V et al. (2000) Induction of ribosomal genes and hepatocyte hypertrophy by adenovirus-mediated expression of c-Myc in vivo. Proc Natl Acad Sci U S A 97:11198-202